Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals

Liver International

Volumn 35, Issue s1, 2015, Pages 51-55

  Rockstroh, Jürgen K ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cirrhosis; Direct acting antivirals; Hepatis C; HIV; Liver disease

Indexed keywords

ANTIVIRAL AGENTS;

COINFECTION; DRUG EFFECTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; METHODS; PATIENT SELECTION; PHYSIOLOGY; TRENDS;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; PATIENT SELECTION;

EID: 84919609116     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12721     Document Type: Review

References (17)

1. Easterbrook P. Global burden of hepatitis B and C, and HIV co-infection. International HIV/Viral Hepatitis Co-Infection Satellite Meeting Melbourne, 18-19 July 2014
2. Rockstroh JK, Peters L, Grint D, et al.; EuroSIDA in EuroCoord. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. J Hepatol 2013; 59: 213-20.
3. Morlat P, Roussillon C, Henard S, et al.; ANRS EN20 Mortalité 2010 Study Group. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28: 1181-91.
4. Lacombe K, Rockstroh JK. HIV and viral hepatitis co-infections: advances and challenges. Gut 2012; 61(Suppl. 1): i47-58.
5. Rockstroh JK, Bhagani S. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals. BMC Med 2013; 11: 234.
6. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double blind, controlled phase 2 trial. Lancet Infect. Dis 2013; 13: 597-605.
7. Sulkowski M, Sherman K, Dieterich D, et al. Telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1 infection in HIV-infected patients. Ann Intern Med 2013; 159: 86-96.
8. Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV-HCV coinfected patients failing peginterferon-ribavirin (ANRS HC26TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; pii: ciu659 [Epub ahead of print].
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
10. Lo Re V 3rd, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160: 369-79.
11. Berenguer J, Zamora FX, Carrero A, et al.; GESIDA HIVHCV Cohort Study Group. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014;66:280-7.
12. Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: 36-49.
13. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
14. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV-1 coinfection. JAMA 2014; 312: 353-61.
15. Molina JM, Orkin C, Iser DM, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2). AIDS 2014. 20th International AIDS Conference. July 20-25, 2014. Melbourne. Abstract MOAB0105LB.
16. Osinusi A, Townsend K, Nelson A et al.; NIAID ERADICATE Study Team. Use of sofosbuvir/ledipasvir fixed dose combination for treatment of genotype-1 infection in patients coinfected with HIV. 49thEuropean Association for the Study of the Liver International Liver Congress (EASL 2014). London, April 9-13, 2014. Abstract O14.
17. Sulkowski M, Eron JJ, Wyles D, et al.; TURQUOISE-I: safety and efficacy of ABT-450/r/ombitasvir, dasabuvir, and ribavirin in patients co-infected with hepatitis C and HIV-1. AIDS 2014. 20th International AIDS Conference. July 20-25, 2014. Melbourne. Abstract MOAB0104LB.